<DOC>
	<DOCNO>NCT01007721</DOCNO>
	<brief_summary>The objective current study investigate efficacy , safety tolerability BI 671800 ED use three dose level BI 671800 ED ( 50 mg , 200 mg 400 mg ) , administer twice daily compare FP ( fluticasone propionate ) nasal 100 mcg per nostril qd morning Montelukast 10 mg qd give 2 week patient SAR ( seasonal allergic rhinitis ) season use environmental exposure chamber patient know sensitive aero-allergen Dactylis glomerata .</brief_summary>
	<brief_title>Randomized , Placebo Controlled , Crossover Study Environmental Challenge Chamber Assess Safety &amp; Efficacy Three Oral Doses BI 671800 Versus Fluticasone Propionate Montelukast Sensitive Seasonal Allergic Rhinitis Patients Out Season</brief_title>
	<detailed_description />
	<mesh_term>Rhinitis , Allergic</mesh_term>
	<mesh_term>Rhinitis</mesh_term>
	<mesh_term>Rhinitis , Allergic , Seasonal</mesh_term>
	<mesh_term>Fluticasone</mesh_term>
	<mesh_term>Montelukast</mesh_term>
	<criteria>1 . Signed informed consent consistent ICHGCP guideline ( International Conference Harmonisation Good Clinical Practice ) local legislation prior studyrelated procedure , include medication washout restriction . 2 . Male female , diagnosis seasonal allergic rhinitis physician positive skin prick test Dactylis glomerata within 12 month prior Visit 2 3 . TNSS ( total nasal symptom score ) less equal 2 start challenge Visit 2 TNSS &gt; 5 least 2hbaseline ECC exposure 4 . 18 65 year age ( age inclusive ) 5 . Nonsmoker exsmoker cigarette smoke history less equal 10 packyears ( smoke cessation least one year prior enrolment ) negative urinary cotinine screening ( Visit 1 ) 6 . Ability comply requirement , medication restriction ( see 4.2.2 ) procedure study protocol include AM1Â® device rescue medication use . 7 . Prebronchodilator FEV1 ( forced expiratory volume one second ) equal great 80 % predict value ( European Community Steel Coal ) screen 8 . BMI 18 35 ( Body Mass Index ) 9 . Negative breath alcohol , urine cotinine drug test screen ( Visit 1 ) 1 . Significant pulmonary disease allergic rhinitis ( mild intermittent asthma manage SABA ( short act bronchodilator ) alone ) medical conditions* may , opinion investigator result follow : put patient risk participation study influence result study ( determined medical history , examination clinical investigation screen ) cause concern regard patient 's ability participate study . *e.g . cardiac , gastrointestinal , hepatic , renal , metabolic , dermatologic , neurological , haematological , oncological psychiatric . Patients malignancy patient undergone resection , radiation chemotherapy within past 5 year . Patients treat basal cell carcinoma fully cure squamous cell carcinoma allow . 2 . Any nasal sinusoidal disease condition discretion investigator ( i.e . nasal polyp , frequent nose bleed ) may influence study result 3 . Respiratory tract infection asthma exacerbation 4 week prior Visit 1 screen baseline period . 4 . Thoracotomy pulmonary resection . 5 . Previous participation study ( receipt randomize treatment ) active participation current interventional study . 6 . Patients clinically relevant abnormal baseline haematology , blood chemistry , urinalysis screening , abnormality defines significant disease define exclusion criterion No . 1 . Patients randomise increase liver transaminase ( AST ALT great two fold upper limit normal screening ) . Laboratory testing may repeat randomization . 7 . Significant alcohol drug abuse within past 2 year ( see exclusion criterion No . 1 ) 8 . Patients know hypersensitivity component investigational treatment ( see section 4.1.1 ) fluticasone propionate nasal spray montelukast salbutamol component . 9 . Patients take CYP2C8 substrate restrict amiodarone , amodiaquine , paclitaxel , rosiglitazone , pioglitazone , repaglinide CYP2C9 substrate restrict warfarin , tolbutamide , phenytoin , losartan acenocoumarol . 10 . Patients treat follow medication give interval respective Visit : Before Visit 2 An investigational drug within 1 month six half life ( whichever great ) Any immunomodulatory therapy since specific positive skin prick test . A biological base antagonist therapy include Omalizumab , immune modulator therapy within 6 month A systemic ( intravenous , intramuscular oral ) corticosteroid within 3 month The following medication within 4 week : topical steroid , change prescription medication The following medication within 2 week : LABA ( long act beta agonist ) , methylxanthines , leukotriene modifier , antihistamine , oral decongestant , antirhinitis therapy ( i.e. , decongestant , herbal , anticholinergic ) , hayfever medication , tricyclic antidepressant , aspirin NSAIDs ( non steroidal anti inflammatory drug ) ( occasional pain relief , paracetamol may use ) , oral beta 2 agonist Before Visit 1 : Short act bronchodilator within 6 hour baseline pulmonary function test 11 . Patients risk prolonged QT interval effect include : A marked baseline prolongation QT interval electrocardiogram demonstration QTcB interval ( Bazett 's correction formula ) &gt; 450 m A history additional risk factor TdP ( Torsades de pointes ) e.g. , heart failure , hypokalemia , family , history Long QT Syndrome , etc . The use concomitant medication know prolong QT/QTc interval 12 . Pregnant nursing woman 13 . Women childbearing potential use highly effective method birth control .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2014</verification_date>
</DOC>